- Advertise
- About OncLive
- Editorial Board
- MJH Life Sciences brands
- Contact Us
- Privacy
- Terms & Conditions
- Do Not Sell My Information
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
© 2025 MJH Life Sciences™ and OncLive - Clinical Oncology News, Cancer Expert Insights. All rights reserved.
Latest Conference Articles
The OncLive® Conference page includes a listing of all conferences covered by OncLive®, including the ASCO, ESMO, SITC, EHA, ASH, and SABCS annual meetings, as well as the Chemotherapy Foundation Symposium and Miami Breast Cancer Conference, among many others. Conference coverage incorporates articles and interviews in written and video format.
Poll Results Spotlight Key Lung Cancer Abstracts Driving Anticipation Ahead of ESMO 2025
September 26th 2025, 8:22pm
OncLive social media polls reveal which lung cancer abstracts are generating excitement ahead of the 2025 ESMO Congress.
Poll Results Spotlight Key GU Cancer Abstracts Driving Anticipation Ahead of ESMO 2025
September 26th 2025, 6:00pm
OncLive social media polls reveal which prostate, kidney, and bladder cancer abstracts are generating excitement ahead of the 2025 ESMO Congress.
Breast Cancer Experts: Key ADC Developments and CDK 4/6 Inhibitor Updates Set to Dominate ESMO 2025
September 25th 2025, 1:00pm
Ahead of the 2025 ESMO Congress, breast cancer experts share the most anticipated research being presented during the meeting.
Myeloma Experts Summarize Key Themes From the 22nd Annual IMS Meeting and Exposition
September 23rd 2025, 5:48pm
International Myeloma Society Annual Meeting
OncLive heard from myeloma experts about the biggest developments in the field at the 22nd Annual International Myeloma Society Meeting and Exposition.
Isa-VRd Displays High VGPR or Better Rate in Transplant-Ineligible Newly Diagnosed Multiple Myeloma
September 22nd 2025, 1:00pm
International Myeloma Society Annual Meeting
Isa-VRd produced a VGPR or better rate of 87.8% in transplant-ineligible newly diagnosed multiple myeloma.
Sonrotoclax Plus Dexamethasone Generates Early Efficacy in R/R Myeloma
September 21st 2025, 10:00am
International Myeloma Society Annual Meeting
Sonrotoclax plus dexamethasone was well tolerated and produced early efficacy signals in relapsed/refractory multiple myeloma with t(11;14).
BKd Produces Robust Responses in Relapsed/Refractory Multiple Myeloma
September 20th 2025, 9:10pm
International Myeloma Society Annual Meeting
Belantamab mafodotin plus carfilzomib and dexamethasone was active in patients with relapsed/refractory multiple myeloma.
Belantamab Mafodotin/Lenalidomide Maintenance Displays Manageable Eye Toxicity Profile in Newly Diagnosed Myeloma
September 20th 2025, 8:35pm
International Myeloma Society Annual Meeting
Belantamab mafodotin plus lenalidomide maintenance was active and had an expected safety profile in transplant-eligible, newly diagnosed myeloma.
Belantamab Mafodotin Shows Single-Agent Activity in Relapsed/Refractory Multiple Myeloma
September 20th 2025, 7:10pm
International Myeloma Society Annual Meeting
Belantamab mafodotin monotherapy was active and safe in patients with relapsed/refractory multiple myeloma.
Dr Leleu on QOL Outcomes With SC Isatuximab Via On-Body Delivery in R/R Myeloma
September 20th 2025, 6:23pm
International Myeloma Society Annual Meeting
Xavier Leleu, MD, PhD, discusses the role of subcutaneous isatuximab delivered via an on-body delivery system in patients with relapsed/refractory multiple myeloma.
ATLAS Analysis Supports KRd After ASCT in High-Risk, Newly Diagnosed Myeloma
September 20th 2025, 5:47pm
International Myeloma Society Annual Meeting
Carfilzomib, lenalidomide, and dexamethasone after transplant improved PFS and OS in high-risk, newly diagnosed multiple myeloma.
Subcutaneous Isatuximab Delivery Is Noninferior to IV Administration in Multiple Myeloma
September 20th 2025, 5:35pm
International Myeloma Society Annual Meeting
Efficacy and pharmacokinetic measures with IV vs SC isatuximab delivered via an on-body injector were comparable in patients with multiple myeloma.
Daratumumab/Lenalidomide Maintenance Boosts MRD Negativity in Newly Diagnosed Myeloma
September 20th 2025, 5:15pm
International Myeloma Society Annual Meeting
Maintenance therapy with daratumumab plus lenalidomide led to higher MRD-negativity conversion rates vs lenalidomide alone in newly diagnosed myeloma.
Dr Anderson on Daratumumab/Lenalidomide Maintenance After ASCT in Newly Diagnosed Myeloma
September 20th 2025, 3:27pm
International Myeloma Society Annual Meeting
Larry Anderson, MD, PhD, discusses updated efficacy and safety findings of subcutaneous daratumumab plus lenalidomide in newly diagnosed multiple myeloma following autologous stem cell transplant.
Linvoseltamab Yields Favorable Safety Profile and Antimyeloma Activity in High-Risk Smoldering Myeloma
September 19th 2025, 11:28pm
International Myeloma Society Annual Meeting
Linvoseltamab monotherapy generated responses and had a favorable safety profile with low rates of high-grade TEAEs in high-risk smoldering myeloma.
Belantamab Mafodotin/Bortezomib/Dexamethasone Yields PFS, OS Benefits in Lenalidomide-Refractory Myeloma
September 19th 2025, 10:14pm
International Myeloma Society Annual Meeting
Treatment with BVd led to favorable survival outcomes and prolonged responses vs DVd in lenalidomide-refractory patients with multiple myeloma.
Daratumumab/Ixazomib Quadruplet Yields Durable Efficacy in Transplant-Ineligible or -Deferred, Newly Diagnosed Myeloma
September 19th 2025, 9:35pm
International Myeloma Society Annual Meeting
The combination of daratumumab, lenalidomide, ixazomib, and dexamethasone was efficacious in transplant-ineligible, newly diagnosed myeloma.
Stretched Dosing Schedule of Belantamab Mafodotin Plus VRd Is Active, Safe in Transplant-Ineligible Myeloma
September 19th 2025, 9:31pm
International Myeloma Society Annual Meeting
The addition of belantamab mafodotin to standard-of-care VRd proved feasible as frontline therapy in newly diagnosed multiple myeloma.
Dr Nadeem on Efficacy and Safety of Arlo-Cel for R/R Myeloma
September 19th 2025, 9:10pm
International Myeloma Society Annual Meeting
Omar Nadeem, MD, discusses updated data with the GPRC5D-targeted CAR T-cell therapy arlocabtagene autoleucel in relapsed/refractory multiple myeloma.
Dr Rodriguez-Otero on Data for Linvoseltamab in High-Risk Smoldering Myeloma
September 19th 2025, 8:41pm
International Myeloma Society Annual Meeting
Paula Rodriguez-Otero, MD, discusses safety and efficacy findings with linvoseltamab, a bispecific antibody targeting BCMA, in patients with high-risk smoldering multiple myeloma.